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The utility of wound débridement has expanded to include the management of all chronic wounds, even in the absence
of infection and gross necrosis. Biofilm, metalloproteases on the wound base, and senescent cells at the wound edge
irreversibly change the physiology of wound healing and contribute to a pathologic, chronic inflammatory environment.
The objective of this review is to provide surgeons with a baseline understanding of the processes of débridement in the
noninfected wound. (J Vasc Surg 2010;52:31S-6S.)The most general definition of débridement is the pro-
cess in which all materials incompatible with healing are
removed from a wound. This definition has grown broader
with time and classically involves the surgical excision of all
grossly infected and necrotic tissue. Military surgeons in the
18th and 19th centuries, most notably the Belgian Antione
Depage, developed techniques of aggressive excision on the
battlefields of Europe to prevent gangrene and save lives.1
We now know, however, that tissue does not have to be
actively infected or necrotic to impair the biologic wound
healing processes of the body. Effective débridement can be
achieved with nonsurgical means in some cases, while the
growing utility and importance of serial débridement of
chronic wounds is becoming more apparent.2-13
The intended emphasis of this article is to provide a
review of the processes of débridement in the noninfected
wound. The goals are to (1) focus on the pathophysiology
of the target tissue causing wound-healing impairment in
the absence of infection, and (2) recommend specific tech-
niques for débridement.
INFLAMMATION VS INFECTION
Because inflammation is an objective hallmark of both
infected and chronic wounds, it can often represent a
clinical challenge to determine whether a lower extremity
wound is actively infected or simply chronically inflamed.
One might easily say that all infection is inflammatory but
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doi:10.1016/j.jvs.2010.06.006that not all inflammation is infectious. Further clouding
this issue is the reality that all wounds are expected to have
at least some degree of bacterial colonization, even in the
absence of active clinical infection. Indeed60% of chronic
wounds contain biofilm.14 It is important to determine at
which point critical colonization has been reached or the
level at which the type and quantity of bacteria begin to
cause active infection. Although the presence of any bacte-
ria is certain to have at least some effect on the biologic
processes of wound healing, specific treatment and surgical
interventions should depend on whether critical coloniza-
tion is present with active infection.
These seemingly subtle differences should guide the
surgical treatment plan and the target tissues of débride-
ment. Surrounding erythema, swelling, induration, tender-
ness, and malodor are the expected characteristics of an
infected wound. The target tissue for débridement in this
situation is the en masse excision of all grossly infected and
necrotic tissue. The wound requires exploration to discover
any deep pockets, abscesses, or tracking along fascial and
tendinous structures. Adjunctive antibiotic therapy is re-
quired to help in eradicating the bacteria.
On the other hand, a noninfected but chronic wound
can still be expected to have a rim of surrounding erythema,
even without other local clinical signs of infection. Peri-
wound erythema does not necessarily indicate a cellulitis
from an infection source but rather inflammation in re-
sponse to an open lesion. The target tissue for débridement
in this case is somewhat different. Certainly, any necrotic
tissue and bacterial colonization should be removed, but
equally important is targeting the débridement toward the
cells on the wound edge and base that are irreversibly fixed
in the inflammatory stage of wound healing.
The important distinction here is that in the absence of
infection, a wound can be caught in a chronic inflammatory
phase, despite bacteria having been controlled with topical
and systemic antibiotics. Débridement is required to con-
vert the chronic wound bed into an acute wound. Another
situation is where a wound may have the clinical appearance
of local infection and periwound cellulitis, but the erythema
is due to ischemic rubor. Here, all local signs of infection
disappear with simple elevation of the limb. In this case, the
target tissue for intervention is not local but involves sys-
temic revascularization. These three situations of peri-
wound erythema around a wound have a similar presenta-
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of surgical target tissue.
Surgeons working with the lower extremity must de-
velop a sharp clinical acumen to determine the difference
between an infected wound and one that is merely chron-
ically inflamed. It is important to appreciate that most of
our laboratory and advanced imaging diagnostic tools pro-
vide clinicians with general information about inflamma-
tion and not specifically infection. These are indirect mark-
ers that should guide clinical judgment. Lower extremity
wound infection is primarily a clinical diagnosis, and expe-
rience is required to make the correct diagnosis.
ACUTE VS CHRONIC WOUND HEALING
Chronic inflammation is an important consideration
not just in the clinical presentation of a wound but also in
terms of the pathophysiology of wound development.
Acute wounds should proceed quickly and uneventfully
through the normal stages of the healing processes: inflam-
mation, proliferation, and maturation.15 These stages rep-
resent normal physiology after a linear pathway. There is a
distinct start point represented by wound formation and a
clear end point marked by wound closure. Unfortunately
for chronic wounds, the progression along this linear path-
way is arrested, and one sees the pathophysiology of a
chronic cycle without a clear end point of wound closure.
A chronic wound is usually arrested in the inflammatory
stage and cannot progress further. Infection is not required
for a wound to become fixed in the inflammatory stage,
although it could be a contributing factor. Abnormal met-
alloproteases produced by necrotic tissue, foreign material,
and bacteria impede the body’s attempt to heal by over-
whelming the building blocks—chemotactant factors,
growth factors, mitogens—needed for normal wound heal-
ing. This hostile environment enables bacteria to proliferate
and could lead to critical colonization. This environment
further inhibits healing by producing destructive enzymes
and consuming the local resources—oxygen, nutrition,
and building blocks—necessary for healing.
Further, there are two significant changes to the cells of
a chronic wound, specifically those on the wound base and
edge, which are affected by this pathophysiology even in
the absence of infection. The presence of senescent cells
and biofilm irreversibly impair acute wound healing. Fibro-
blasts, one of the normal building blocks of an acute
wound, have demonstrated phenotypically and irreversibly
altered differences in the setting of chronic wounds.16
From a mitotic standpoint, these cells are less active and
have decreased ability to perform the DNA replication
required for proliferation.17 They also produce abnormal
proteolytic enzymes and metalloproteases that contribute
to the chronic wound environment.18-20 And similar to the
critical contamination concept when considering bacteria,
there may be a “critical number” of senescent cells within a
wound that make healing unlikely regardless of interven-
tion.21,22
In addition, the role of bacterial biofilms in chronic
wound development has become increasingly apparent inrecent years. According to a study that used scanning
electron microscopy, 60% of chronic wounds contained a
biofilm compared with only 6% of acute wounds.14 A biofilm
is a polymicrobial sessile community of phenotypically-altered
microorganisms that develop on the surface of chronic
wounds, requiring only the presence of bacteria and not
critical colonization.23,24 These bacterial cells bind to each
other and the wound base, producing an extrapolymetric
substance varying in depth from a single cell layer to a thick
community of cells.
Quorum sensing describes the process through which
the cells are phenotypically altered and able to operate with
down-regulated cellular activity and at a lower metabolic
level.25,26 The embedded nature and altered metabolic
state of the biofilm represent an effective barrier to tradi-
tional forms of intervention, including topical treatments
and antibiotic therapy.
The biofilm and senescent cells on the wound base and
periphery comprise the primary target tissues for surgical
intervention of the noninfected wound. One may equate
the excision of these cells from a noninfected wound as the
equivalent of the excision of most if not all of the bacteria
from an infected wound.
SURGICAL DÉBRIDEMENT TECHNIQUES
The use of atraumatic surgical techniques should be max-
imized when performing débridement to avoid damaging the
underlying healthy tissue. One should also attempt to leave
behind as much viable tissue as possible, because these rem-
nants will form the building blocks for subsequent healing in
vascular in-growth and the delivery of growth factors and
nutrients. Traumatic techniques that will cause untoward
damage to otherwise healthy and biologic tissue include the
charring of tissue with electrocautery and tying off large
clumps of tissue with suture. Although both may be necessary
to a lesser degree to achieve adequate hemostasis, their use
should be avoided as much as possible and topical hemostatic
agents and pressure should be used instead.
The specific tools of débridement will also have an
effect on the underlying viable tissue. Whether in the office
or operating room, sterile surgical instruments are recom-
mended over the use of disposable suture removal kits. The
latter are usually dull and may crush and damage the
remaining skin edge and underlying tissue. The basic tools
of débridement include blades, forceps, scissors, curettes,
and rongeurs (Fig 1).
Only the tissue that is being excised should be grasped
with the forceps, and #10 or #20 blades are used to sequen-
tially slice off thin layers of tissue. These blades should be
changed frequently because they can dull quickly. Sharp-
edged curettes are useful for removing the proteinaceous
coagulum that accumulates on top of both fresh and
chronic granulation tissue. Rongeurs are useful for remov-
ing hard-to-reach soft tissue and for débriding or biopsying
bone. An air-driven or electrical sagittal saw can serially
remove thin layers of bone until normal cortex and marrow
is reached. Cutting burrs and rasps permit fine débridement
of the bone surface until the telltale punctate bleeding at
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planned, it is important to keep tissues moist to prevent
dessication between débridements. This holds particularly
true for subcutaneous tissue, fascia, and tendons.
It is important to pay attention to the colors of the
wound bed during débridement. Wounds should be
débrided until all grey and black substances have been
removed, and only red (muscle), white (tendon, bone,
fascia), and/or yellow (subcutaneous fat) tissues remain.
Examples of this can be seen in Figs 2-4, and 6. One useful
débridement technique is to paint methylene blue over the
entire wound bed before débridement to help the surgeon
ensure complete, thorough débridement of the wound
(Figs 4-6). The blue staining binds irreversibly to the
superficial cells of the wound base as well as any exposed
crevices or tracks. This technique helps ensure that no
exposed or contaminated tissue is left in the wound bed. By
removing all of the blue-stained tissue, it is easier to ensure
that the entire wound surface is débrided and that colo-
nized cells on the wound surface are removed.
Those basic principles hold true for the débridement of
both infected and noninfected wounds, but special consid-
eration must be paid to noninfected wounds. Because of
the senescent cells around the wound edge, it may be
necessary to excise a 2- to 3-mm rim around the periphery
of the wound. Senescent cells can have the appearance of an
epithelial rim and may very well bleed with superficial
débridement. They have been found several millimeters
away from the edge of chronic venous leg ulcers even
though the tissue appears healthy.27 Although it may seem
overly aggressive to remove a rim of apparently normal-
Fig 1. The basic tools of débridement include rongeurs, curettes,
scissors, forceps, and surgical blades.appearing tissue from a noninfected wound, it is necessaryto remove the senescent cells to recreate an acute wound so
that the wound healing cascade can get a fresh start (Figs 5
and 6).
The biofilm that develops on the wound base may also
have the appearance of granular and viable tissue. It is
important to remember that this is essentially an invisible
“layer” formed by an extracellular matrix that binds to the
wound base, whether dermis, fascia, muscle, tendon, or
bone. Because the biofilm binds irreversibly, it is necessary
to aggressively débride the wound base with blades, cu-
rettes, burrs, and/or electrical blades. It may not be
enough to curette deeper, relatively avascular tissues such as
tendons and bone.28 For this reason, the authors have
recently adopted the use of a hydrosurgical débrider that
uses a water jet with up to 15,000 psi to débride these
tissues (Fig 3, 6). The Venturi effect caused by this
high-pressure water jet evacuates the débrided tissue into
the stream of water, thus separating it from underlying
tissue. This type of hydrosurgical débridement has been
shown to more effectively and efficiently reduce bacteria
and biofilm.29 It also removes unwanted tissue and de-
bris with greater precision than with a scalpel by cutting
less than a millimeter at a time, therefore minimizing
peripheral tissue damage and reducing the removal of
Fig 2. Chronic wound before débridement. Note the colors of
the wound bed. All fibrotic grey and necrotic black tissue must be
totally removed to achieve effective débridement.healthy tissue.
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The presence of peripheral vascular disease and chronic
Fig 3. Chronic wound during débridement. Hydrosurgical
débridement of the wound bed is performed to remove all nonvi-
able tissue. Note the difference in wound colors compared with the
predébridement picture (Fig 2). Only granulation tissue (red),
tendon, bone, and fascia (white), and subcutaneous fat (yellow)
tissue remains.
Fig 4. Chronic, noninfected venous stasis wound. Note the clinical
appearance and colors of this chronic wound before débridement.limb ischemia deserves special mention, as noninfectedwounds have slightly more flexibility in the timing of a
débridement. In the presence of active infection, a wound
should be débrided immediately regardless of the need for
revascularization. However, if a wound or dry gangrene is
present without clinical signs of infection, then revascular-
ization should be performed first. The blood supply to a
wound should be optimized before débridement to ensure
that potentially viable tissue is not unnecessarily removed.
This can be achieved by waiting 4 to 8 days after an open
bypass or 3 to 4 weeks after endovascular surgery before
performing any definitive débridement on a noninfected
wound.30 The difference between viable and nonviable
tissue becomes markedly clouded in the presence of isch-
emia, even without the presence of infection.
If dry gangrene is present in a vascularized limb, closely
Fig 5. Methylene blue has been painted on the entire wound bed
intraoperatively. The wound periphery is also outlined with a
marking pen to demonstrate senescent cells at the wound edge that
need to be removed.
Fig 6. Venous stasis wound during débridement. Débridement is
performed until all markings are removed, effectively turning the
chronic wound into an acute wound. Note the red, white, and
yellow wound colors compared with Fig 4.observe for evidence of new tissue growth underneath the
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growth, then the wound should be débrided. However, if
there is evidence of new tissue growth, then the wound may
be observed until the eschar falls off or until signs of
infection necessitate débridement.
NONSURGICAL DÉBRIDEMENT TECHNIQUES
Not all patients are surgical candidates, and not all
wounds need to go directly to the operating room for
immediate débridement. Several nonsurgical débridement
techniques may be used in these situations. Wet-to-dry
dressings, where the saline-moistened gauze is allowed to
dry on the wound and then is physically ripped off, were a
standard mechanical débridement technique. Although
this nonselective form of débridement effectively removes
dead tissue, it can harm the viable tissue left behind and can
be painful in the sensate patient. Therefore, newer tech-
niques, such as topical enzymatic débriding agents that can
digest the collagen in necrotic tissue, are now considered
first-line treatments.31-35
Maggot débridement therapy (MDT) had been used
for centuries to heal wounds but has only been recently
revisited and revised as a form of therapy when surgical
intervention is not an option. It has also been found to be
surprisingly effective in the presence of resistant strains of
bacteria. Medical maggots, most commonly the blowfly
species Lucilia sericata, are selective in débriding necrotic,
fibrotic tissue while sparing healthy tissue.
In addition to the secretion of proteolytic digestive
enzymes that dissolve necrotic tissue, L sericata has also
been shown to secrete various cytokines and tissue growth
factors that can increase local tissue oxygenation.36 It has
therefore been proposed that MDT not only débrides and
disinfects wounds but also promotes healing. Studies have
demonstrated that MDT is a cost-effective, efficient
method in débridement of ulcerations in nonsurgical pa-
tients with relatively very few side effects.36-38 However,
aside from débridement of venous wounds, Dumville et
al39 found that MDT did not increase healing rates and was
associated with significantly more pain in the patients re-
ceiving MDT compared with hydrogel.
Débridement using noncontact low-frequency ultra-
sound therapy also appears to play a role in débriding and
healing chronic ulcers.40-44 This technique creates a com-
bination of cavitation and microstreaming that provides a
mechanical energy capable of altering cell membrane activ-
ity, and in turn, cellular activity.44 It helps separate necrotic
tissue from the underlying bed, kills bacteria, and disrupts
biofilm. It also may induce wound healing through a broad
range of factors, including leukocyte adhesion, growth
factor production, collagen production, increased angio-
genesis, increased macrophage responsiveness, increased
fibrinolysis, and increased nitric oxide levels.45 One study
suggests that ultrasound débridement may disrupt quorum
sensing within biofilms, thereby leading to decreased coor-
dinated virulence38; however, further research in this area is
needed.CONCLUSION
Panuncialman and Falanga16,45 have recently reviewed
the science of wound bed preparation and underscore the
importance of débridement as a critical step in the transi-
tion of a chronic wound into an acute wound. They appro-
priately caution, however, that débridement is just one of
the required interventions and that it can be difficult to
determine when débridement has achieved its maximum
effect. Patients must also be systemically optimized from a
metabolic standpoint, with considerations of nutritional
status, smoking status, and glycemic control at the fore-
front. The vasculature must be regulated, both in arterial
supply maximization and periwound edema minimization.
Other potential causes of wound formation, such as in-
creased areas of pressure in the setting of neuropathy, must
also be addressed.
Although there are many potential causes for the
pathophysiology of wound chronicity in the absence of
infection, the irreversible development of senescent cells
around the wound edge and biofilm on the wound base
should not be overlooked. Wounds that do not progress
toward closure at a consistent rate (about a 50% decrease in
wound volume in 4 weeks or a 10% to 15% decrease in
wound volume per week), should be considered chronic
and warrant a change in intervention.46 Débridement, even
in the absence of infection, remains a cornerstone of these
potential interventions.
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